Conference Coverage

Featured Image - Laboratory. Courtesy 2019 Fotolia

Study Demonstrates Superior Efficacy and Cytotoxicity of Femtogenix’s Sequence-selective DNA-interactive Payload

Data verifying a favorable toxicity profile and potent efficacy of a novel pyrridinobenzodiazepine (PDD) antibody-drug conjugate payload platform in...
Featured Image - San Diego, CA at night. Courtesy 2019 Fotolia

Zymeworks Wins Best ADC Platform Technology Award for ZymeLink

Zymeworks, a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics including bispecific antibodies and bispecific antibody-drug conjugates across a wide range...
Downtown San Diego, CA. Courtesy: 2019 David Cruz/Sunvalley Communication

Abzena to Offer New, Integrated, Clinical Translation Service

Abzena, a life sciences company providing a series of specific serviced for the development of antibody-drug conjugates, earlier this...
The AACR 2019 Annual Meeting - Poster Session during the American Association for Cancer Research (AACR) Annual Meeting, Sunday March 31, 2019. Courtesy: © AACR/Todd Buchanan 2019

Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at Bolt Biotherapeutics

Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the...

Sutro Biopharma to Receive Milestone Payment from Merck KGaA for Bispecific ADC Candidate

Sutro Biopharma has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA,...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development

Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development...

Comprehensive Service Accelerates Development of ADCs and Reduces Time to Clinic

A new service called ADC Express™services, launched by MilliporeSigma, allows for the rapid production of Antibody-drug Conjugates or ADCs....

World ADC 2019: Maximizing the Clinical Therapeutic Index of Antibody-drug Conjugates

With five approved and commercially available antibody-drug conjugates and nearly 100 in various stages of clinical development, it is...

ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression

The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

FORWARD II Triplet Combination Demonstrates Encouraging Anti-tumor Activity

Safety and overall response data from the Phase Ib FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with...